SCHEMBL4861034

SCHEMBL4861034

CCc1ccc(C(O)c2ncccc2OCOCC[Si](CC)(CC)CC)cc1

nearest known ligand 0.31

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.31
KCNH2 Q12809 1/20 0.31
LMNA P02545 1/20 0.30
P4HB P07237 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6385422 0.76 KDM4E (0.35) LMNA
SCHEMBL4858597 0.72 S1PR4 (0.43) LMNA
SCHEMBL4854930 0.71 P4HB (0.39) LMNAP4HB
SCHEMBL4859922 0.69 IDO1 (0.33) LMNA
SCHEMBL5656046 0.69 GAA (0.42) PRKDCKCNH2LMNA
SCHEMBL4706964 0.67 ACHE (0.36)
SCHEMBL5208805 0.64 MEN1 (0.41)
SCHEMBL14369411 0.64 LMNA (0.50) LMNA
SCHEMBL4854942 0.64 L3MBTL1 (0.41) PRKDCKCNH2LMNA
SCHEMBL21609588 0.64 PRKDC (0.42) PRKDCKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439232-B2 Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-10-21 US disclosed
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same TAISHO PHARMACEUTICAL CO., LTD. (JP) 2006-08-31 US disclosed
EP-1609799-A1 HETEROARYL 5-THIO-BETA-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME TAISHO PHARMACEUTICAL CO., LTD (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194809-A1 Heteroaryl 5-thio-beta-d-gucopyranoside derivatives and therapeutic agents for diabetes containing the same SLC5A2, SLC5A1, UGGT1 PRKDC 3605/4885KCNH2 1398/4885LMNA 4561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.